<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We used gene targeting in mice to insert a His(6)-tagged mouse c-Myc cDNA, Myc(His), head to head into the mouse immunoglobulin heavy-chain locus, Igh, just 5' of the intronic enhancer, Emu </plain></SENT>
<SENT sid="1" pm="."><plain>The insertion of Myc(His) mimicked both the human t(8;14)(q24;q32) translocation that results in the activation of MYC in human endemic Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and the homologous mouse T(12;15) translocation that deregulates Myc in certain mouse <z:hpo ids='HP_0011857'>plasmacytomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Beginning at the age of 6 months, Myc(His) transgenic mice developed B-cell and plasma <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, such as IgM(+) lymphoblastic B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, Bcl-6(+) diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and CD138(+) <z:hpo ids='HP_0011857'>plasmacytomas</z:hpo>, with an overall incidence of 68% by 21 months </plain></SENT>
<SENT sid="3" pm="."><plain>Molecular studies of lymphoblastic B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the most prevalent <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (50% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>), showed that the <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were clonal, overexpressed Myc(His), and exhibited the P2 to P1 promoter shift in Myc expression, a hallmark of MYC/Myc deregulation in human endemic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and mouse <z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Only 1 (6.3%) of 16 lymphoblastic B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> contained a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-typical point mutation in the amino-terminal transactivation domain of Myc(His), suggesting that most of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are derived from naive, pregerminal center B cells </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve (46%) of 26 lymphoblastic B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> exhibited changes in the p19(<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">Arf</z:e>)-Mdm2-p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor axis, an important pathway for Myc-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that Myc(His) insertion into Igh predictably induces B-cell and <z:mp ids='MP_0009440'>plasma-cell tumors</z:mp> in mice, providing a valuable mouse model for understanding the transformation-inducing consequences of the MYC/Myc-activating endemic Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> t(8;14)/<z:hpo ids='HP_0011857'>plasmacytoma</z:hpo> T(12;15) translocation </plain></SENT>
</text></document>